Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $53.5 million.

  • Oncology Institute's Non-Current Assets fell 1470.89% to $53.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $226.0 million, marking a year-over-year decrease of 1144.97%. This contributed to the annual value of $60.3 million for FY2024, which is 828.63% down from last year.
  • As of Q3 2025, Oncology Institute's Non-Current Assets stood at $53.5 million, which was down 1470.89% from $55.0 million recorded in Q2 2025.
  • Oncology Institute's 5-year Non-Current Assets high stood at $230.3 million for Q1 2021, and its period low was $49.4 million during Q4 2021.
  • Its 5-year average for Non-Current Assets is $102.3 million, with a median of $65.7 million in 2023.
  • Over the last 5 years, Oncology Institute's Non-Current Assets had its largest YoY gain of 16577.36% in 2022, and its largest YoY loss of 7104.99% in 2022.
  • Oncology Institute's Non-Current Assets (Quarter) stood at $49.4 million in 2021, then surged by 165.77% to $131.2 million in 2022, then crashed by 49.91% to $65.7 million in 2023, then decreased by 8.29% to $60.3 million in 2024, then fell by 11.23% to $53.5 million in 2025.
  • Its last three reported values are $53.5 million in Q3 2025, $55.0 million for Q2 2025, and $57.2 million during Q1 2025.